DefinitionThis section has been translated automatically.
Abciximab is a chimeric Fab fragment of a chimeric antibody of mice and humans against glycoprotein IIb/IIIa receptors. Abciximab binds with high affinity to activated forms of the receptor, thereby reducing fibrinogen binding to the secretory function of platelets.
The binding of Abciximab to the receptors is irreversible.
IndicationThis section has been translated automatically.
Approval for the treatment of unstable angina pectoris and for coronary interventions
You might also be interested in
Dosage and method of useThis section has been translated automatically.
Initially 0.25 mg/kg body weight, then 0.125 ug/kg/min over 12 hours.
Dose adjustment for liver and kidney failure.
ContraindicationThis section has been translated automatically.
Severe renal insufficiency
PreparationsThis section has been translated automatically.
ReoPro®
LiteratureThis section has been translated automatically.
- HA Neumann (2014) The coagulation system. ABW-Scientific Publisher GmbH Berlin
Prof. Dr. med. Peter Altmeyer